Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Alzheimers Q&A: How can we manage the upcoming holiday season?on November 23, 2020 at 2:30 am
Caregiving for a loved one with Alzheimer's disease or dementia is highly stressful, and getting through the holiday season can be particularly difficult.
- Polly Gillespie: I'll have what David Attenborough is havingon November 21, 2020 at 4:00 pm
I can’t hide. I wanted to write about the experience of loving a parent with Alzheimers. How the reality of it is so confronting and terrifying for some of us, but as I began to log on and get ...
- Being Around Loved Ones, Woman Gets Job To Be In Nursing Homeon November 20, 2020 at 11:02 pm
Nursing homes across this country still remain on lockdown in many states. As cases rise, seniors are being robbed of the opportunity to visit with family members. But Chris Conte shows us how some ...
- Test for Alzheimers ‘focuses’ on the eyeson November 19, 2020 at 4:11 am
MIAMI – The number of Americans living with Alzheimer’s is growing, and along with efforts to develop effective treatments for the disease, researchers are looking into ways to more easily ...
- 'Alive Inside' doc shows how music can combat Alzheimers and dementiaon November 18, 2020 at 6:01 pm
Many have dementia or Alzheimers, most are forgotten and rarely get a visitor. Filmmaker Michael Rossato-Bennett lets his images do the most powerful talking as viewers see elder after elder spark ...
- Understanding Dementia from the Insideon November 17, 2020 at 8:25 am
(The five most common types are Alzheimers, Vascular Dementia, Lewy-Body Dementia, Parkinsons and Frontotemporal.) Before COVID shut all in-person presentations down last spring, I heard a moving talk ...
- Francis Corr: Police concerned for missing 73-year-old Edinburgh woman who has Alzheimerson November 12, 2020 at 1:10 pm
Inspector Caroline Flynn, based at Drylaw, said: "Frances is in the early stages of Alzheimers so she may appear confused or lost. "We're urgently appealing for anyone who has any information ...
- FDA panel weighs approval of Alzheimers drug that claims to slow mental declineon November 6, 2020 at 5:35 am
WASHINGTON - According to the Alzheimer's Association, more than 5 million Americans suffer from Alzheimer's Disease and as of November 2020, one drug company claims it has created a medicine that ...
- Alzheimers Drugs Market Size, Trend, Strategy Analysis & Overview 2030 - AC Immune, F. Hoffmann-La Roche, Novartison October 30, 2020 at 5:47 am
Alzheimer’s drugs are the medications that reduce the symptoms of the disease or in few cases also control the behavioral symptoms. At present, no medication is prescribed for the said disease.
via Bing News